Enhanced tumor suppression in colorectal cancer via berberine-loaded PEG-PLGA nanoparticles

Fei Shen1,2, Yun-Sheng Zheng2, Lan Dong2

  • 1Department of General Surgery, The First Affiliated Hospital, Jinan University, Guangzhou, China.

Frontiers in Pharmacology
|November 18, 2024
PubMed

Insights

Berberine (Ber) encapsulated in PEG-PLGA nanocarriers (NPBer) enhances colorectal cancer (CRC) cell apoptosis and inhibits tumor growth. This nanodrug delivery system improves Ber

Area of Science:

  • Oncology
  • Nanotechnology
  • Pharmacology

Background:

  • Colorectal cancer (CRC) is a leading global cancer with poor outcomes.
  • Berberine (Ber), a natural compound, shows potential against CRC but suffers from poor bioavailability.
  • Nanodrug delivery systems offer advantages in drug protection, bioavailability, and reduced toxicity.

Purpose of the Study:

  • To develop and evaluate Berberine-loaded PEG-PLGA nanocarriers (NPBer) for enhanced colorectal cancer therapy.
  • To investigate the in vitro and in vivo anti-cancer mechanisms of NPBer compared to free Berberine.

Main Methods:

  • Nanoprecipitation was used to encapsulate Berberine into PEG-PLGA nanocarriers, forming NPBer.
  • In vitro studies utilized flow cytometry and CCK8 assays to assess NPBer uptake and cytotoxicity in HCT116 CRC cells.
  • RNA-sequencing (RNA-Seq) analyzed transcriptomic alterations induced by Free Ber and NPBer treatments.
  • In vivo studies evaluated NPBer's tumor targeting, accumulation, and anti-proliferative effects.

Main Results:

  • NPBer demonstrated enhanced cellular uptake and stronger inhibition of HCT116 CRC cell proliferation compared to Free Ber.
  • RNA-Seq revealed that Free Ber induced cellular aging, ferroptosis, apoptosis, and modulated key CRC signaling pathways (Wnt, TGF-beta, Hippo, mTOR).
  • NPBer significantly improved in vivo drug delivery, enhanced apoptosis via mitochondrial autophagy, and inhibited Notch signaling.
  • In vivo, NPBer exhibited superior tumor accumulation, sustained drug targeting, induced maximal apoptosis, and effectively inhibited HCT116 tumor growth.

Conclusions:

  • PEG-PLGA nanocarrier encapsulation enhances Berberine's anti-cancer efficacy against colorectal cancer.
  • NPBer represents a promising therapeutic strategy for colorectal cancer by improving drug delivery and augmenting antitumor mechanisms.